GGrantIndex
← Search

14 Functional Genomics Core

$232,381P30FY2020CANIH

University Of Tx Md Anderson Can Ctr, Houston TX

Investigators

Linked publications, trials & patents

Trial NCT07407920Trial NCT07349641Trial NCT06651580Trial NCT05681026Trial NCT05223036Trial NCT05078866Trial NCT05057312Trial NCT05054296Trial NCT05044546Trial NCT05023967Trial NCT05011045Trial NCT04875728Trial NCT04870645Trial NCT04810091Trial NCT04751422Trial NCT04740164Trial NCT04668300Trial NCT04615013Trial NCT04505267Trial NCT04484909Trial NCT04483349Trial NCT04481204Trial NCT04474301Trial NCT04458610Trial NCT04447222Trial NCT04435691Trial NCT04430725Trial NCT04407247Trial NCT04373720Trial NCT04317781Trial NCT04311723Trial NCT04310826Trial NCT04310397Trial NCT04265430Trial NCT04257045Trial NCT04256941Trial NCT04239989Trial NCT04239976Trial NCT04239157Trial NCT04236882Trial NCT04228042Trial NCT04220827Trial NCT04220775Trial NCT04220008Trial NCT04219969Trial NCT04219904Trial NCT04216732Trial NCT04216563Trial NCT04216524Trial NCT04216472Trial NCT04215029Trial NCT04200534Trial NCT04199026Trial NCT04196972Trial NCT04189783Trial NCT04189770Trial NCT04189757Trial NCT04188418Trial NCT04188405Trial NCT04186884Trial NCT04186832Trial NCT04185337Trial NCT04181463Trial NCT04171622Trial NCT04171219Trial NCT04171037Trial NCT04169763Trial NCT04169737Trial NCT04169542Trial NCT04160052Trial NCT04151082Trial NCT04150939Trial NCT04140487Trial NCT04135326Trial NCT04134208Trial NCT04132843Trial NCT04132505Trial NCT04132440Trial NCT04129138Trial NCT04128748Trial NCT04128501Trial NCT04127721Trial NCT04125914Trial NCT04119037Trial NCT04106843Trial NCT04106245Trial NCT04090619Trial NCT04090567Trial NCT04087057Trial NCT04083378Trial NCT04082572Trial NCT04074746Trial NCT04066894Trial NCT04062305Trial NCT04062266Trial NCT04058964Trial NCT04054245Trial NCT04054167Trial NCT04054154Trial NCT04053517

Abstract

PROJECT SUMMARY: FUNCTIONAL GENOMICS CORE (FGC) Functional genomics employs multiple technologies and genetic tools to study the complicated interactions between genotype and phenotype on a genome-wide scale. Genome-scale gain- and loss-of-function genetic screens are powerful tools for conducting such studies. The mission of the Functional Genomics Core (FGC; previously the CCSG Developing core shRNA and ORFeome Core) is to provide researchers at MD Anderson Cancer Center with cutting-edge technologies to study gene functions in cell-based assays. The FGC utilizes open reading frame (ORF), short hairpin RNA (shRNA), and guided RNA (gRNA) libraries to conduct genome- wide screens to identify oncogenes, tumor suppressors, metastasis regulators, drug resistance?conferring genes, and new therapeutic targets. Dr. Mien-Chie Hung, vice president for basic research and the chair of the Department of Molecular and Cellular Oncology, is the director of the FGC, and Dr. Dihua Yu is the co-director. During the current grant cycle MD Anderson provided $285,151 to purchase capital equipment and prior to 2012, provided funds to purchase FGC's libraries, including the pGIPZ shRNA library (human and mouse), human ORFeome Collaboration library, and Precision LentiORF library from GE Dharmacon and a human genome- wide pooled shRNA library from Cellecta. The FGC also has access to the Toronto KnockOut v3 human pooled gRNA library from Dr. Moffat's laboratory at the University of Toronto. Currently, the FGC provides 1) individual shRNA or ORF clones; 2) retro- and lenti-virus packaging; 3) custom shRNA or ORF libraries; 4) gene-knockout cell lines using CRISPR/Cas9 technology; and 5) project services to help researchers optimize screening assays, perform screens, and analyze data. The requested FGC grant Yr44 budget is $150,977/year; CCSG support would provide 33% of the budget. Since its inception, the FGC has provided services to 176 cancer center members in 64 departments at MD Anderson, representing all 16 CCSG programs. A total of 162 principal investigators have peer-reviewed support. During Yr42, all 80 users representing the 16 CCSG programs had received peer-reviewed funding. Most usage was by the Cancer Biology and Metastasis, Brain Cancer, and Breast Cancer CCSG programs, each of which was responsible for 12% of the total usage. During the grant period, the FGC facilitated 156 peer-reviewed publications, including 128 (82%) in journals with IF >5 and 59 (38%) in journals with IF >10, such as Nature, Cell, and Lancet Oncol. The FGC specific aims are: Aim 1: To provide functional genomics services to cancer center members; Aim 2: To perform genetic screens for basic/translational research and drug discovery; Aim 3: To implement new functional genomic technologies and augment existing services; Aim 4: To offer training and consultation to FGC users.

View original record on NIH RePORTER →